The Case for Dosimetry in Alpha-Emitter Therapy

Research output: Contribution to journalArticlepeer-review

Abstract

Despite ongoing efforts with new chemotherapeutics, small-molecule inhibitors and biologics, patients with distant metastases continue to have a grim prognosis. Radiopharmaceutical therapy (RPT) with alpha-particle–emitting radionuclides has shown efficacy against widespread disease. Alpha-particle emitters are particularly effective because their short range and high energy deposit density lead to complex and largely irreparable DNA double-strand breaks. The high potency against tumors can also lead to high toxicity. Unlike most systemic treatment of cancer, the biodistribution of RPT agents may be imaged in humans using nuclear medicine imaging modalities. In this context, dosimetry provides a precision medicine approach to implementing RPT with alpha-emitters.

Original languageEnglish (US)
Pages (from-to)S45-S46
JournalJournal of Medical Imaging and Radiation Sciences
Volume50
Issue number4
DOIs
StatePublished - Dec 2019

Keywords

  • Radiopharmaceutical therapy
  • alpha-emitters
  • dosimetry

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'The Case for Dosimetry in Alpha-Emitter Therapy'. Together they form a unique fingerprint.

Cite this